Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ARBUTUS BIOPHARMA CORPORATION

(ABUS)
  Report
Delayed Nasdaq  -  04:00:00 2023-01-27 pm EST
2.930 USD    0.00%
01/27Arbutus Biopharma Corp : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)
AQ
01/27Arbutus Announces Resignation of Board Member
GL
01/27Arbutus Announces Resignation of Board Member
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Arbutus to Present at Jefferies London Healthcare Conference

11/08/2022 | 07:31am EST

WARMINSTER, Pa., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that William Collier, Arbutus’ President and Chief Executive Officer, will present at the Jefferies London Healthcare Conference on Wednesday, November 16, 2022, at 11:30 am GMT / 6:30 am EDT.

A live webcast of the presentation can be accessed through the Investors section of Arbutus’ website at www.arbutusbio.com. An archived replay of the webcast will be available on the Arbutus website after the event.

About Arbutus

Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases. Our current focus areas include Hepatitis B virus (HBV), SARS-CoV-2, and other coronaviruses. To address HBV, we are developing a RNAi therapeutic, an oral PD-L1 inhibitor, and an oral RNA destabilizer that we intend to combine with the aim of providing a functional cure for patients with chronic HBV by suppressing viral replication, reducing surface antigen and reawakening the immune system. We believe our lead compound, AB-729, is the only RNAi therapeutic with evidence of immune re-awakening. It is currently being evaluated in multiple phase 2 clinical trials. We also have an ongoing drug discovery and development program directed to identifying novel, orally active agents for treating coronavirus (including SARS-CoV-2). In addition, we are exploring oncology applications for our internal PD-L1 portfolio. For more information, visit www.arbutusbio.com.

Contact Information

Investors and Media

William H. Collier
President and CEO
Phone: 267-469-0914
Email: ir@arbutusbio.com

Lisa M. Caperelli
Vice President, Investor Relations
Phone: 215-206-1822
Email: lcaperelli@arbutusbio.com


All news about ARBUTUS BIOPHARMA CORPORATION
01/27Arbutus Biopharma Corp : Change in Directors or Principal Officers, Financial Statements a..
AQ
01/27Arbutus Announces Resignation of Board Member
GL
01/27Arbutus Announces Resignation of Board Member
AQ
01/27Arbutus Biopharma Corporation Announces Resignation of Tram Tran from the Board of Dire..
CI
01/05Arbutus Biopharma : Corporate Presentation - January 2023
PU
01/05Arbutus Biopharma Corp : Results of Operations and Financial Condition, Other Events, Fina..
AQ
01/05Arbutus Announces 2023 Corporate Objectives and Provides Financial Update
GL
2022Arbutus Biopharma : Corporate Presentation - December 2022
PU
2022Arbutus Biopharma Says Data Reinforces Antigen-Reducing Capacity of Chronic Hepatitis B..
MT
2022Arbutus Biopharma Corp : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
More news
Analyst Recommendations on ARBUTUS BIOPHARMA CORPORATION
More recommendations
Financials
Sales 2022 52,5 M 39,4 M 39,4 M
Net income 2022 -90,7 M -68,1 M -68,1 M
Net Debt 2022 - - -
P/E ratio 2022 -6,41x
Yield 2022 -
Capitalization 614 M 461 M 461 M
Capi. / Sales 2022 11,7x
Capi. / Sales 2023 21,2x
Nbr of Employees 86
Free-Float 74,2%
Chart ARBUTUS BIOPHARMA CORPORATION
Duration : Period :
Arbutus Biopharma Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ARBUTUS BIOPHARMA CORPORATION
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 3,90 CAD
Average target price 7,27 CAD
Spread / Average Target 86,3%
EPS Revisions
Managers and Directors
William H. Collier President, Chief Executive Officer & Director
David C. Hastings Chief Financial & Accounting Officer
Frank M. Torti Chairman
Michael J. Sofia Chief Scientific Officer
Michael J. McElhaugh Chief Operating Officer
Sector and Competitors